New interview with CEO Dr. Nina Webster and Pitt Street Research, filmed 18th March.
Points of interest are mentioned include recent results, future trial end points, strong negotiation position due to premium (derisked) CR, fast track approvals (China might be happy with data on hand* no need for full scale trial in China) , 80% of market negations (USA & China.)
Kidney disease sounds like a massive unmet need in China too.
https://youtu.be/ypOTL7r8Bxg?si=3ZnQZQplDhpJ6kPh
DXB Media thread., page-114
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
-0.020(5.33%) |
Mkt cap ! $195.1M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.0¢ | 35.5¢ | $1.409M | 3.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 101933 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 20948 | 1 |
View Market Depth
| Last trade - 16.10pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
36.0¢ |
Change
-0.020 ( 4.00 %) |
||||
| Open | High | Low | Volume | ||
| 38.0¢ | 38.5¢ | 35.5¢ | 2613498 | ||
| Last updated 15.59pm 20/05/2024 ? | |||||
| DXB (ASX) Chart |